Phase II Trial of Bevacizumab Plus Etoposide for Patients With Recurrent Malignant Glioma
Exploratory, single-arm, ph II study designed to assess anti-tumor activity of
combinatorial regimen consisting of Etoposide + bevacizumab among pts w RMG. Primary
endpoint of study is probability of progression-free survival at 6 mths. Important secondary
objective is to further assess safety of Etoposide & bevacizumab for pts w RMG.
If study demonstrates that combinatorial regimen of Etoposide + bevacizumab is associated w
encouraging anti-tumor activity among pts w RMG, further assessment of regimen in additional
ph II & possibly ph III studies, will be considered.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
6 mth progression-free survival
David A. Reardon, MD
Duke University Health System
United States: Institutional Review Board
|Duke University Health System||Durham, North Carolina 27705|